BACKGROUND: Halofuginone, an inhibitor of collagen type I synthesis, is an anti-angiogenic agent. Here we evaluated the efficacy of halofuginone to inhibit prostate cancer (PC) xenografts representing various phenotypes of the disease. METHODS: An androgen-dependent (CWR22), an androgen-independent (PC3), and a neuroendocrine (WISH-PC2) PC xenograft were used. Halofuginone was given orally or injected intraperitoneally. Tumor size, collagen alpha1(I) gene expression (in situ hybridization), collagen content (sirius red staining), angiogenesis (immunohistochemistry with factor VIII antibodies), and apoptosis/necrosis (DNA fragmentation) were evaluated. RESULTS: Halofuginone inhibited the growth of all subcutaneously implanted xenografts and of WISH-PC2 when transplanted orthotopically. The effect was dose-dependent (WISH-PC2) and accompanied by decrease in plasma PSA levels (CWR22). In all xenografts, halofuginone inhibited collagen alpha1(I) gene expression, reduced collagen content, and endothelial cell number resulting in an increase in apoptosis/necrosis. CONCLUSIONS: Oral administration of halofuginone slowed the progression of PC xenografts representing a broad range of phenotypes. Halofuginone may become a new modality for PC prevention. Copyright 2002 Wiley-Liss, Inc.
BACKGROUND:Halofuginone, an inhibitor of collagen type I synthesis, is an anti-angiogenic agent. Here we evaluated the efficacy of halofuginone to inhibit prostate cancer (PC) xenografts representing various phenotypes of the disease. METHODS: An androgen-dependent (CWR22), an androgen-independent (PC3), and a neuroendocrine (WISH-PC2) PC xenograft were used. Halofuginone was given orally or injected intraperitoneally. Tumor size, collagen alpha1(I) gene expression (in situ hybridization), collagen content (sirius red staining), angiogenesis (immunohistochemistry with factor VIII antibodies), and apoptosis/necrosis (DNA fragmentation) were evaluated. RESULTS:Halofuginone inhibited the growth of all subcutaneously implanted xenografts and of WISH-PC2 when transplanted orthotopically. The effect was dose-dependent (WISH-PC2) and accompanied by decrease in plasma PSA levels (CWR22). In all xenografts, halofuginone inhibited collagen alpha1(I) gene expression, reduced collagen content, and endothelial cell number resulting in an increase in apoptosis/necrosis. CONCLUSIONS: Oral administration of halofuginone slowed the progression of PC xenografts representing a broad range of phenotypes. Halofuginone may become a new modality for PC prevention. Copyright 2002 Wiley-Liss, Inc.
Authors: Danièle Taras; Jean-Frédéric Blanc; Anne Rullier; Nathalie Dugot-Senant; Ingrid Laurendeau; Ivan Bièche; Mark Pines; Jean Rosenbaum Journal: Neoplasia Date: 2006-04 Impact factor: 5.715
Authors: Merav Leiba; Jana Jakubikova; Steffen Klippel; Constantine S Mitsiades; Teru Hideshima; Yu-Tzu Tai; Adi Leiba; Mark Pines; Paul G Richardson; Arnon Nagler; Kenneth C Anderson Journal: Br J Haematol Date: 2012-04-26 Impact factor: 6.998
Authors: Henry B Koon; Barbara Fingleton; Jeannette Y Lee; Julia T Geyer; Ethel Cesarman; Robert A Parise; Merrill J Egorin; Bruce J Dezube; David Aboulafia; Susan E Krown Journal: J Acquir Immune Defic Syndr Date: 2011-01-01 Impact factor: 3.731
Authors: Patricia Juárez; Khalid S Mohammad; Juan Juan Yin; Pierrick G J Fournier; Ryan C McKenna; Holly W Davis; Xiang H Peng; Maria Niewolna; Delphine Javelaud; John M Chirgwin; Alain Mauviel; Theresa A Guise Journal: Cancer Res Date: 2012-09-20 Impact factor: 12.701
Authors: Meagan M Grudzien; Philip Steven Low; Peter C Manning; Melissa Arredondo; Robert J Belton; Romana A Nowak Journal: Fertil Steril Date: 2009-01-09 Impact factor: 7.329